Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

Prashanth Rawla, Tagore Sunkara, Vinaya Gaduputi, Prashanth Rawla, Tagore Sunkara, Vinaya Gaduputi

Abstract

Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be due to lack of appropriate diagnosis, treatment and cataloging of cancer cases. Because patients seldom exhibit symptoms until an advanced stage of the disease, pancreatic cancer remains one of the most lethal malignant neoplasms that caused 432,242 new deaths in 2018 (GLOBOCAN 2018 estimates). Globally, 458,918 new cases of pancreatic cancer have been reported in 2018, and 355,317 new cases are estimated to occur until 2040. Despite advancements in the detection and management of pancreatic cancer, the 5-year survival rate still stands at 9% only. To date, the causes of pancreatic carcinoma are still insufficiently known, although certain risk factors have been identified, such as tobacco smoking, diabetes mellitus, obesity, dietary factors, alcohol abuse, age, ethnicity, family history and genetic factors, Helicobacter pylori infection, non-O blood group and chronic pancreatitis. In general population, screening of large groups is not considered useful to detect the disease at its early stage, although newer techniques and the screening of tightly targeted groups (especially of those with family history), are being evaluated. Primary prevention is considered of utmost importance. Up-to-date statistics on pancreatic cancer occurrence and outcome along with a better understanding of the etiology and identifying the causative risk factors are essential for the primary prevention of this disease.

Keywords: Epidemiology; Etiology; Incidence; Mortality; Pancreatic cancer; Pancreatitis; Prevention; Risk factors; Survival; Trends.

Conflict of interest statement

None of the authors have conflict of interest.

Figures

Figure 1
Figure 1
Map shows estimated age-standardized incidence rates (ASR) for pancreatic cancer worldwide in 2018, including both sexes and all ages (reproduced from http://globocan.iarc.fr/ [2]).
Figure 2
Figure 2
(a) Bar chart shows country-specific incidence age-standardized rates by sex for pancreatic cancer in 2018. Source: GLOBOCAN 2018 [2]. (b) Bar chart shows country-specific mortality age-standardized rates by sex for pancreatic cancer in 2018. Source: GLOBOCAN 2018 [2].
Figure 3
Figure 3
Map shows estimated age-standardized mortality rates (ASR) for pancreatic cancer worldwide in 2018, including both sexes and all ages (reproduced from http://globocan.iarc.fr/ [2]).
Figure 4
Figure 4
Bar chart shows estimated age-standardized incidence and mortality rates (ASR) for pancreatic cancer in world areas in 2018, including both sexes and all ages (reproduced from http://globocan.iarc.fr/ [2]).
Figure 5
Figure 5
Trends in pancreatic cancer incidence and mortality predicted for the years 2018 to 2040 (reproduced from http://globocan.iarc.fr/ [28]). (a) Estimated incidence from 2018 to 2040, in both sexes and all ages (0 - 70+ years). Asia: 214,499 in 2018 and +190,532 in 2040, (+88.8% of increase); Europe: 132,559 in 2018 and +38,855 in 2040 (+29.3%); North America: 56,002 in 2018 and +28,325 in 2040 (+50.6%); Africa: 16,059 in 2018 and +18,327 in 2040 (+114.1%); Latin America and the Caribbean: 35,270 in 2018 and +35,007 in 2040 (+99.3%); Oceania: 4,529 in 2018 and +3,268 in 2040 (+72.2%). (b) Estimated mortality from 2018 to 2040, in both sexes and all ages (0 to 70+ years). Asia: 200,681 in 2018 and +182,127 in 2040 (+90.8%); Europe: 128,045 in 2018 and +40,444 in 2040 (+31.6%); North America: 50,745 in 2018 and +29,011 in 2040 (57.2%); Africa: 15,458 in 2018 and +17,744 in 2040 (+114.8%); Latin America and the Caribbean: 33,311 in 2018 and +33,637 in 2040 (+101.0%); Oceania: 4,002 in 2018 and +2,985 in 2040 (74.6%)
Figure 6
Figure 6
Pancreatic cancer, age-standardized 1-year and 5-year net survival, adults (age: 15 - 99 years), England and Wales 1971 - 2011 (reproduced from reference [34]).

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
    1. Ferlay J EM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; Available from: , Accessed 05 October 2018.
    1. Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, Negri E. et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4) Ann Oncol. 2012;23(7):1880–1888. doi: 10.1093/annonc/mdr541.
    1. Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64(7):2634–2638. doi: 10.1158/0008-5472.CAN-03-3823.
    1. Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Neoptolemos J, Real FX. et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15(1):8–18. doi: 10.1016/j.pan.2014.10.001.
    1. Organization WH. World Cancer Report 2014. Accessed 06 October 2018.
    1. De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89(8):626–632.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi: 10.3322/caac.21442.
    1. Mohammed S, Van Buren G 2nd, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol. 2014;20(28):9354–9360.
    1. SEER Cancer Statistics Review, 1975-2013 [Internet]. National Cancer Institue, Bethesda, MD. 2016. Available from: . Accessed 05 October 2018.
    1. Malvezzi M, Carioli G, Bertuccio P, Rosso T, Boffetta P, Levi F, La Vecchia C. et al. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol. 2016;27(4):725–731. doi: 10.1093/annonc/mdw022.
    1. Bosetti C, Bertuccio P, Negri E, La Vecchia C, Zeegers MP, Boffetta P. Pancreatic cancer: overview of descriptive epidemiology. Mol Carcinog. 2012;51(1):3–13. doi: 10.1002/mc.20785.
    1. Ezzati M, Henley SJ, Lopez AD, Thun MJ. Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer. 2005;116(6):963–971. doi: 10.1002/ijc.21100.
    1. Willett WC. Diet and cancer. Oncologist. 2000;5(5):393–404. doi: 10.1634/theoncologist.5-5-393.
    1. Genkinger JM, Spiegelman D, Anderson KE, Bernstein L, van den Brandt PA, Calle EE, English DR. et al. A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. Int J Cancer. 2011;129(7):1708–1717. doi: 10.1002/ijc.25794.
    1. Jarosz M, Sekula W, Rychlik E. Influence of diet and tobacco smoking on pancreatic cancer incidence in poland in 1960-2008. Gastroenterol Res Pract. 2012;2012:682156. doi: 10.1155/2012/682156.
    1. Avgerinos DV, Bjornsson J. Malignant neoplasms: discordance between clinical diagnoses and autopsy findings in 3,118 cases. APMIS. 2001;109(11):774–780. doi: 10.1034/j.1600-0463.2001.d01-145.x.
    1. Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bull World Health Organ. 2005;83(3):171–177.
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi: 10.1016/j.ejca.2012.12.027.
    1. Parkin DM, Boyd L, Walker LC. 16. The fraction of cancer attributable to lifestyle and environmental factors in the UK in 2010. Br J Cancer. 2011;105(Suppl 2):S77–81. doi: 10.1038/bjc.2011.489.
    1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. doi: 10.3322/canjclin.55.2.74.
    1. Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6(4):321–337. doi: 10.1177/1756283X13478680.
    1. Levi F, Lucchini F, Negri E, La Vecchia C. Pancreatic cancer mortality in Europe: the leveling of an epidemic. Pancreas. 2003;27(2):139–142. doi: 10.1097/00006676-200308000-00006.
    1. Sens MA, Zhou X, Weiland T, Cooley AM. Unexpected neoplasia in autopsies: potential implications for tissue and organ safety. Arch Pathol Lab Med. 2009;133(12):1923–1931.
    1. Lambe M, Eloranta S, Wigertz A, Blomqvist P. Pancreatic cancer; reporting and long-term survival in Sweden. Acta Oncol. 2011;50(8):1220–1227. doi: 10.3109/0284186X.2011.599338.
    1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694–9705. doi: 10.3748/wjg.v22.i44.9694.
    1. Wu W, He X, Yang L, Wang Q, Bian X, Ye J, Li Y. et al. Rising trends in pancreatic cancer incidence and mortality in 2000-2014. Clin Epidemiol. 2018;10:789–797. doi: 10.2147/CLEP.S160018.
    1. Ferlay J EM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer; Accessed 07 October 2018. Available from: .
    1. Weiss W, Benarde MA. The temporal relation between cigarette smoking and pancreatic cancer. Am J Public Health. 1983;73(12):1403–1404. doi: 10.2105/AJPH.73.12.1403.
    1. Agarwal B, Correa AM, Ho L. Survival in pancreatic carcinoma based on tumor size. Pancreas. 2008;36(1):e15–20. doi: 10.1097/mpa.0b013e31814de421.
    1. United States National Cancer Institute. Pancreatic cancer: statistics 2018, May. Available from: . Accessed 07 October 2018.
    1. Rossi S, Baili P, Capocaccia R, Caldora M, Carrani E, Minicozzi P, Pierannunzio D. et al. The EUROCARE-5 study on cancer survival in Europe 1999-2007: Database, quality checks and statistical analysis methods. Eur J Cancer. 2015;51(15):2104–2119. doi: 10.1016/j.ejca.2015.08.001.
    1. Survival of cancer patients in Europe. European Cancer Registry (EUROCARE). . 2015, October. Accessed 05 October 2018.
    1. Cancer Research UK, , Accessed October 20 2018.
    1. Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, Alnwick-Allu K. et al. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. J Gastrointest Cancer. 2015;46(3):201–211. doi: 10.1007/s12029-015-9724-1.
    1. Oh SY, Edwards A, Mandelson MT, Lin B, Dorer R, Helton WS, Kozarek RA. et al. Rare long-term survivors of pancreatic adenocarcinoma without curative resection. World J Gastroenterol. 2015;21(48):13574–13581. doi: 10.3748/wjg.v21.i48.13574.
    1. Dimastromatteo J, Houghton JL, Lewis JS, Kelly KA. Challenges of pancreatic cancer. Cancer J. 2015;21(3):188–193. doi: 10.1097/PPO.0000000000000109.
    1. Yamamoto T, Yagi S, Kinoshita H, Sakamoto Y, Okada K, Uryuhara K, Morimoto T. et al. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis. World J Gastroenterol. 2015;21(1):262–268. doi: 10.3748/wjg.v21.i1.262.
    1. American Cancer Society. . Accessed 10 October 2018.
    1. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–1389. doi: 10.1016/j.ejca.2007.12.015.
    1. Brenner H, Hakulinen T. Population-based monitoring of cancer patient survival in situations with imperfect completeness of cancer registration. Br J Cancer. 2005;92(3):576–579. doi: 10.1038/sj.bjc.6602323.
    1. Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: A review. Cancer Lett. 2016;381(1):269–277. doi: 10.1016/j.canlet.2016.07.022.
    1. Iarc Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004;83:1–1438.
    1. Kuzmickiene I, Everatt R, Virviciute D, Tamosiunas A, Radisauskas R, Reklaitiene R, Milinaviciene E. Smoking and other risk factors for pancreatic cancer: a cohort study in men in Lithuania. Cancer Epidemiol. 2013;37(2):133–139. doi: 10.1016/j.canep.2012.10.001.
    1. Mizuno S, Nakai Y, Isayama H, Kawahata S, Saito T, Takagi K, Watanabe T. et al. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Pancreas. 2014;43(7):1014–1017. doi: 10.1097/MPA.0000000000000158.
    1. Pelucchi C, Galeone C, Polesel J, Manzari M, Zucchetto A, Talamini R, Franceschi S. et al. Smoking and body mass index and survival in pancreatic cancer patients. Pancreas. 2014;43(1):47–52. doi: 10.1097/MPA.0b013e3182a7c74b.
    1. Rastogi T, Devesa S, Mangtani P, Mathew A, Cooper N, Kao R, Sinha R. Cancer incidence rates among South Asians in four geographic regions: India, Singapore, UK and US. Int J Epidemiol. 2008;37(1):147–160. doi: 10.1093/ije/dym219.
    1. Iodice S, Gandini S, Maisonneuve P, Lowenfels AB. Tobacco and the risk of pancreatic cancer: a review and meta-analysis. Langenbecks Arch Surg. 2008;393(4):535–545. doi: 10.1007/s00423-007-0266-2.
    1. Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC, Michaud DS, Severinsen MT, Overvad K, Olsen A. et al. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;126(10):2394–2403. doi: 10.1002/ijc.24907.
    1. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F. et al. Cigarette smoking and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium. Am J Epidemiol. 2009;170(4):403–413. doi: 10.1093/aje/kwp134.
    1. Tan D. Smoking in Asia: a looming health epidemic. Asian Scientist Magazine Read more from Asian Scientist Magazine at: . 2012. Accessed 05 October 2018.
    1. Wang YT, Gou YW, Jin WW, Xiao M, Fang HY. Association between alcohol intake and the risk of pancreatic cancer: a dose-response meta-analysis of cohort studies. BMC Cancer. 2016;16:212. doi: 10.1186/s12885-016-2241-1.
    1. Lucenteforte E, La Vecchia C, Silverman D, Petersen GM, Bracci PM, Ji BT, Bosetti C. et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4) Ann Oncol. 2012;23(2):374–382. doi: 10.1093/annonc/mdr120.
    1. Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, Corrao G. et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer. 2010;126(6):1474–1486. doi: 10.1002/ijc.24936.
    1. Michaud DS, Vrieling A, Jiao L, Mendelsohn JB, Steplowski E, Lynch SM, Wactawski-Wende J. et al. Alcohol intake and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan) Cancer Causes Control. 2010;21(8):1213–1225. doi: 10.1007/s10552-010-9548-z.
    1. Rahman F, Cotterchio M, Cleary SP, Gallinger S. Association between alcohol consumption and pancreatic cancer risk: a case-control study. PLoS One. 2015;10(4):e0124489. doi: 10.1371/journal.pone.0124489.
    1. Davoodi SH, Malek-Shahabi T, Malekshahi-Moghadam A, Shahbazi R, Esmaeili S. Obesity as an important risk factor for certain types of cancer. Iran J Cancer Prev. 2013;6(4):186–194.
    1. Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer. 2003;89(3):519–523. doi: 10.1038/sj.bjc.6601140.
    1. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–1638. doi: 10.1056/NEJMoa021423.
    1. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, Abbruzzese JL. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301(24):2553–2562. doi: 10.1001/jama.2009.886.
    1. Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, Cade JE. et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(4):843–852. doi: 10.1093/annonc/mdr398.
    1. Michaud DS, Skinner HG, Wu K, Hu F, Giovannucci E, Willett WC, Colditz GA. et al. Dietary patterns and pancreatic cancer risk in men and women. J Natl Cancer Inst. 2005;97(7):518–524. doi: 10.1093/jnci/dji094.
    1. Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1):186–198. doi: 10.1093/ije/dyu240.
    1. Lightsey D. Comment on 'Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies'. Br J Cancer. 2012;107(4):754–755. doi: 10.1038/bjc.2012.111.
    1. Stolzenberg-Solomon RZ, Cross AJ, Silverman DT, Schairer C, Thompson FE, Kipnis V, Subar AF. et al. Meat and meat-mutagen intake and pancreatic cancer risk in the NIH-AARP cohort. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2664–2675. doi: 10.1158/1055-9965.EPI-07-0378.
    1. Beaney AJ, Banim PJR, Luben R, Lentjes MAH, Khaw KT, Hart AR. Higher meat intake is positively associated with higher risk of developing pancreatic cancer in an age-dependent manner and are modified by plasma antioxidants: a prospective cohort study (EPIC-Norfolk) using data from food diaries. Pancreas. 2017;46(5):672–678. doi: 10.1097/MPA.0000000000000819.
    1. Paluszkiewicz P, Smolinska K, Debinska I, Turski WA. Main dietary compounds and pancreatic cancer risk. The quantitative analysis of case-control and cohort studies. Cancer Epidemiol. 2012;36(1):60–67. doi: 10.1016/j.canep.2011.05.004.
    1. Larsson SC, Wolk A. Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies. Br J Cancer. 2012;106(3):603–607. doi: 10.1038/bjc.2011.585.
    1. Miller PE, Alexander D. A review and meta-analysis of prospective studies of red and processed meat and pancreatic cancer. FASEB J. 2016;30:902–909.
    1. Aschebrook-Kilfoy B, Cross AJ, Stolzenberg-Solomon RZ, Schatzkin A, Hollenbeck AR, Sinha R, Ward MH. Pancreatic cancer and exposure to dietary nitrate and nitrite in the NIH-AARP Diet and Health Study. Am J Epidemiol. 2011;174(3):305–315. doi: 10.1093/aje/kwr092.
    1. Rohrmann S, Linseisen J, Nothlings U, Overvad K, Egeberg R, Tjonneland A, Boutron-Ruault MC. et al. Meat and fish consumption and risk of pancreatic cancer: results from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2013;132(3):617–624. doi: 10.1002/ijc.27637.
    1. Bao Y, Hu FB, Giovannucci EL, Wolpin BM, Stampfer MJ, Willett WC, Fuchs CS. Nut consumption and risk of pancreatic cancer in women. Br J Cancer. 2013;109(11):2911–2916. doi: 10.1038/bjc.2013.665.
    1. Wu L, Wang Z, Zhu J, Murad AL, Prokop LJ, Murad MH. Nut consumption and risk of cancer and type 2 diabetes: a systematic review and meta-analysis. Nutr Rev. 2015;73(7):409–425. doi: 10.1093/nutrit/nuv006.
    1. Appleby PN, Crowe FL, Bradbury KE, Travis RC, Key TJ. Mortality in vegetarians and comparable nonvegetarians in the United Kingdom. Am J Clin Nutr. 2016;103(1):218–230. doi: 10.3945/ajcn.115.119461.
    1. Ojajarvi IA, Partanen TJ, Ahlbom A, Boffetta P, Hakulinen T, Jourenkova N, Kauppinen TP. et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med. 2000;57(5):316–324. doi: 10.1136/oem.57.5.316.
    1. Bosch de Basea M, Porta M, Alguacil J, Puigdomenech E, Gasull M, Garrido JA, Lopez T. et al. Relationships between occupational history and serum concentrations of organochlorine compounds in exocrine pancreatic cancer. Occup Environ Med. 2011;68(5):332–338. doi: 10.1136/oem.2009.054197.
    1. Porta M, Malats N, Jariod M, Grimalt JO, Rifa J, Carrato A, Guarner L. et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. Lancet. 1999;354(9196):2125–2129. doi: 10.1016/S0140-6736(99)04232-4.
    1. Hartwig A, Kruger I, Beyersmann D. Mechanisms in nickel genotoxicity: the significance of interactions with DNA repair. Toxicol Lett. 1994;72(1-3):353–358. doi: 10.1016/0378-4274(94)90048-5.
    1. Hartwig A, Mullenders LH, Schlepegrell R, Kasten U, Beyersmann D. Nickel(II) interferes with the incision step in nucleotide excision repair in mammalian cells. Cancer Res. 1994;54(15):4045–4051.
    1. Kasprzak KS. The role of oxidative damage in metal carcinogenicity. Chem Res Toxicol. 1991;4(6):604–615. doi: 10.1021/tx00024a002.
    1. Lee YW, Klein CB, Kargacin B, Salnikow K, Kitahara J, Dowjat K, Zhitkovich A. et al. Carcinogenic nickel silences gene expression by chromatin condensation and DNA methylation: a new model for epigenetic carcinogens. Mol Cell Biol. 1995;15(5):2547–2557. doi: 10.1128/MCB.15.5.2547.
    1. Ahamed M, Akhtar MJ, Siddiqui MA, Ahmad J, Musarrat J, Al-Khedhairy AA, AlSalhi MS. et al. Oxidative stress mediated apoptosis induced by nickel ferrite nanoparticles in cultured A549 cells. Toxicology. 2011;283(2-3):101–108. doi: 10.1016/j.tox.2011.02.010.
    1. Schwartz GG, Reis IM. Is cadmium a cause of human pancreatic cancer? Cancer Epidemiol Biomarkers Prev. 2000;9(2):139–145.
    1. Kriegel AM, Soliman AS, Zhang Q, El-Ghawalby N, Ezzat F, Soultan A, Abdel-Wahab M. et al. Serum cadmium levels in pancreatic cancer patients from the East Nile Delta region of Egypt. Environ Health Perspect. 2006;114(1):113–119.
    1. Hartwig A. Mechanisms in cadmium-induced carcinogenicity: recent insights. Biometals. 2010;23(5):951–960. doi: 10.1007/s10534-010-9330-4.
    1. Schwerdtle T, Ebert F, Thuy C, Richter C, Mullenders LH, Hartwig A. Genotoxicity of soluble and particulate cadmium compounds: impact on oxidative DNA damage and nucleotide excision repair. Chem Res Toxicol. 2010;23(2):432–442. doi: 10.1021/tx900444w.
    1. Bertin G, Averbeck D. Cadmium: cellular effects, modifications of biomolecules, modulation of DNA repair and genotoxic consequences (a review) Biochimie. 2006;88(11):1549–1559. doi: 10.1016/j.biochi.2006.10.001.
    1. Candeias S, Pons B, Viau M, Caillat S, Sauvaigo S. Direct inhibition of excision/synthesis DNA repair activities by cadmium: analysis on dedicated biochips. Mutat Res. 2010;694(1-2):53–59. doi: 10.1016/j.mrfmmm.2010.10.001.
    1. Waalkes MP, Cherian MG, Ward JM, Goyer RA. Immunohistochemical evidence of high concentrations of metallothionein in pancreatic hepatocytes induced by cadmium in rats. Toxicol Pathol. 1992;20(3 Pt 1):323–326. doi: 10.1177/019262339202000302.
    1. Overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1–440.
    1. Yorifuji T, Tsuda T, Doi H, Grandjean P. Cancer excess after arsenic exposure from contaminated milk powder. Environ Health Prev Med. 2011;16(3):164–170. doi: 10.1007/s12199-010-0182-x.
    1. Yorifuji T, Tsuda T, Grandjean P. Unusual cancer excess after neonatal arsenic exposure from contaminated milk powder. J Natl Cancer Inst. 2010;102(5):360–361. doi: 10.1093/jnci/djp536.
    1. Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, Bouvard V. et al. A review of human carcinogens - Part C: metals, arsenic, dusts, and fibres. Lancet Oncol. 2009;10(5):453–454. doi: 10.1016/S1470-2045(09)70134-2.
    1. Qin XJ, Hudson LG, Liu W, Ding W, Cooper KL, Liu KJ. Dual actions involved in arsenite-induced oxidative DNA damage. Chem Res Toxicol. 2008;21(9):1806–1813. doi: 10.1021/tx8001548.
    1. Pu YS, Jan KY, Wang TC, Wang AS, Gurr JR. 8-Oxoguanine DNA glycosylase and MutY homolog are involved in the incision of arsenite-induced DNA adducts. Toxicol Sci. 2007;95(2):376–382. doi: 10.1093/toxsci/kfl166.
    1. Reichard JF, Puga A. Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. Epigenomics. 2010;2(1):87–104. doi: 10.2217/epi.09.45.
    1. Brown KM, Arthur JR. Selenium, selenoproteins and human health: a review. Public Health Nutr. 2001;4(2B):593–599. doi: 10.1079/PHN2001143.
    1. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9(7):775–806. doi: 10.1089/ars.2007.1528.
    1. Amaral AF, Cantor KP, Silverman DT, Malats N. Selenium and bladder cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19(9):2407–2415. doi: 10.1158/1055-9965.EPI-10-0544.
    1. Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, Montori VM. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc. 2008;83(1):23–34. doi: 10.4065/83.1.23.
    1. Zhuo H, Smith AH, Steinmaus C. Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature. Cancer Epidemiol Biomarkers Prev. 2004;13(5):771–778.
    1. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev. 2008;3:CD004183. doi: 10.1002/14651858.CD004183.pub3.
    1. Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control. 2005;16(9):1125–1131. doi: 10.1007/s10552-005-0334-2.
    1. Burney PG, Comstock GW, Morris JS. Serologic precursors of cancer: serum micronutrients and the subsequent risk of pancreatic cancer. Am J Clin Nutr. 1989;49(5):895–900. doi: 10.1093/ajcn/49.5.895.
    1. Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, Tanida O. et al. Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett. 2008;259(2):218–230. doi: 10.1016/j.canlet.2007.10.019.
    1. Jackson MI, Combs GF Jr. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care. 2008;11(6):718–726. doi: 10.1097/MCO.0b013e3283139674.
    1. Smith ML, Lancia JK, Mercer TI, Ip C. Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res. 2004;24(3a):1401–1408.
    1. Fowler BA, Whittaker MH, Lipsky M, Wang G, Chen XQ. Oxidative stress induced by lead, cadmium and arsenic mixtures: 30-day, 90-day, and 180-day drinking water studies in rats: an overview. Biometals. 2004;17(5):567–568. doi: 10.1023/B:BIOM.0000045740.52182.9d.
    1. Schrauzer GN. Anticarcinogenic effects of selenium. Cell Mol Life Sci. 2000;57(13-14):1864–1873. doi: 10.1007/PL00000668.
    1. Brotherton L, Welton M, Robb SW. Racial disparities of pancreatic cancer in Georgia: a county-wide comparison of incidence and mortality across the state, 2000-2011. Cancer Med. 2016;5(1):100–110. doi: 10.1002/cam4.552.
    1. Shavers VL, Harlan LC, Jackson M, Robinson J. Racial/ethnic patterns of care for pancreatic cancer. J Palliat Med. 2009;12(7):623–630. doi: 10.1089/jpm.2009.0036.
    1. Ma J, Siegel R, Jemal A. Pancreatic cancer death rates by race among US men and women, 1970-2009. J Natl Cancer Inst. 2013;105(22):1694–1700. doi: 10.1093/jnci/djt292.
    1. American Cancer Society. Cancer Facts and Figures 2014. . 2014. Accessed 05 October 2018.
    1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–1261. doi: 10.1053/j.gastro.2013.01.068.
    1. Arnold LD, Patel AV, Yan Y, Jacobs EJ, Thun MJ, Calle EE, Colditz GA. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Cancer Epidemiol Biomarkers Prev. 2009;18(9):2397–2405. doi: 10.1158/1055-9965.EPI-09-0080.
    1. Pernick NL, Sarkar FH, Philip PA, Arlauskas P, Shields AF, Vaitkevicius VK, Dugan MC. et al. Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians. Pancreas. 2003;26(1):28–32. doi: 10.1097/00006676-200301000-00006.
    1. Dong M, Nio Y, Tamura K, Song MM, Guo KJ, Guo RX, Dong YT. Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol Biomarkers Prev. 2000;9(3):279–284.
    1. Song MM, Nio Y, Dong M, Tamura K, Furuse K, Tian YL, He SG. et al. Comparison of K-ras point mutations at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients. J Surg Oncol. 2000;75(3):176–185. doi: 10.1002/1096-9098(200011)75:3<176::AID-JSO5>;2-W.
    1. Longnecker DS, Karagas MR, Tosteson TD, Mott LA. Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in Asians, blacks, and whites in the United States. Pancreas. 2000;21(4):338–343. doi: 10.1097/00006676-200011000-00003.
    1. Batabyal P, Vander Hoorn S, Christophi C, Nikfarjam M. Association of diabetes mellitus and pancreatic adenocarcinoma: a meta-analysis of 88 studies. Ann Surg Oncol. 2014;21(7):2453–2462. doi: 10.1245/s10434-014-3625-6.
    1. Pezzilli R, Pagano N. Is diabetes mellitus a risk factor for pancreatic cancer? World J Gastroenterol. 2013;19(30):4861–4866. doi: 10.3748/wjg.v19.i30.4861.
    1. McAuliffe JC, Christein JD. Type 2 diabetes mellitus and pancreatic cancer. Surg Clin North Am. 2013;93(3):619–627. doi: 10.1016/j.suc.2013.02.003.
    1. Haugvik SP, Hedenstrom P, Korsaeth E, Valente R, Hayes A, Siuka D, Maisonneuve P. et al. Diabetes, smoking, alcohol use, and family history of cancer as risk factors for pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Neuroendocrinology. 2015;101(2):133–142. doi: 10.1159/000375164.
    1. Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007;96(3):507–509. doi: 10.1038/sj.bjc.6603571.
    1. Rosato V, Polesel J, Bosetti C, Serraino D, Negri E, La Vecchia C. Population attributable risk for pancreatic cancer in Northern Italy. Pancreas. 2015;44(2):216–220. doi: 10.1097/MPA.0000000000000251.
    1. Li D, Tang H, Hassan MM, Holly EA, Bracci PM, Silverman DT. Diabetes and risk of pancreatic cancer: a pooled analysis of three large case-control studies. Cancer Causes Control. 2011;22(2):189–197. doi: 10.1007/s10552-010-9686-3.
    1. Liao KF, Lai SW, Li CI, Chen WC. Diabetes mellitus correlates with increased risk of pancreatic cancer: a population-based cohort study in Taiwan. J Gastroenterol Hepatol. 2012;27(4):709–713. doi: 10.1111/j.1440-1746.2011.06938.x.
    1. Bosetti C, Rosato V, Li D, Silverman D, Petersen GM, Bracci PM, Neale RE. et al. Diabetes, antidiabetic medications, and pancreatic cancer risk: an analysis from the International Pancreatic Cancer Case-Control Consortium. Ann Oncol. 2014;25(10):2065–2072. doi: 10.1093/annonc/mdu276.
    1. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnquist HJ, Larsson J. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993;80(8):1047–1050. doi: 10.1002/bjs.1800800841.
    1. Gullo L, Pezzilli R, Morselli-Labate AM, Italian Pancreatic Cancer Study G. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994;331(2):81–84. doi: 10.1056/NEJM199407143310203.
    1. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA. 1995;273(20):1605–1609. doi: 10.1001/jama.1995.03520440059037.
    1. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–2083. doi: 10.1038/sj.bjc.6602619.
    1. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, Sung B. et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25(9):2097–2116. doi: 10.1007/s11095-008-9661-9.
    1. Jacobs EJ, Chanock SJ, Fuchs CS, Lacroix A, McWilliams RR, Steplowski E, Stolzenberg-Solomon RZ. et al. Family history of cancer and risk of pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) Int J Cancer. 2010;127(6):1421–1428. doi: 10.1002/ijc.25148.
    1. Permuth-Wey J, Egan KM. Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis. Fam Cancer. 2009;8(2):109–117. doi: 10.1007/s10689-008-9214-8.
    1. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med. 2009;133(3):365–374.
    1. Greer JB, Whitcomb DC, Brand RE. Genetic predisposition to pancreatic cancer: a brief review. Am J Gastroenterol. 2007;102(11):2564–2569. doi: 10.1111/j.1572-0241.2007.01475.x.
    1. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378(9791):607–620. doi: 10.1016/S0140-6736(10)62307-0.
    1. Brune KA, Lau B, Palmisano E, Canto M, Goggins MG, Hruban RH, Klein AP. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010;102(2):119–126. doi: 10.1093/jnci/djp466.
    1. Wang L, Brune KA, Visvanathan K, Laheru D, Herman J, Wolfgang C, Schulick R. et al. Elevated cancer mortality in the relatives of patients with pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2829–2834. doi: 10.1158/1055-9965.EPI-09-0557.
    1. Ghiorzo P. Genetic predisposition to pancreatic cancer. World J Gastroenterol. 2014;20(31):10778–10789. doi: 10.3748/wjg.v20.i31.10778.
    1. Shi C, Daniels JA, Hruban RH. Molecular characterization of pancreatic neoplasms. Adv Anat Pathol. 2008;15(4):185–195. doi: 10.1097/PAP.0b013e31817bf57d.
    1. Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J. 2012;18(6):485–491. doi: 10.1097/PPO.0b013e318278c4a6.
    1. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, Hruban RH. et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17% Cancer Res. 2002;62(13):3789–3793.
    1. Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B. et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95(3):214–221. doi: 10.1093/jnci/95.3.214.
    1. Couch FJ, Johnson MR, Rabe KG, Brune K, de Andrade M, Goggins M, Rothenmund H. et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(2):342–346. doi: 10.1158/1055-9965.EPI-06-0783.
    1. Jones S, Hruban RH, Kamiyama M, Borges M, Zhang X, Parsons DW, Lin JC. et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324(5924):217. doi: 10.1126/science.1171202.
    1. Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP. et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010;78(5):490–494. doi: 10.1111/j.1399-0004.2010.01425.x.
    1. Tischkowitz MD, Sabbaghian N, Hamel N, Borgida A, Rosner C, Taherian N, Srivastava A. et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009;137(3):1183–1186. doi: 10.1053/j.gastro.2009.06.055.
    1. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012;51(1):14–24. doi: 10.1002/mc.20855.
    1. Risch HA, Yu H, Lu L, Kidd MS. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst. 2010;102(7):502–505. doi: 10.1093/jnci/djq007.
    1. Risch HA, Lu L, Kidd MS, Wang J, Zhang W, Ni Q, Gao YT. et al. Helicobacter pylori seropositivities and risk of pancreatic carcinoma. Cancer Epidemiol Biomarkers Prev. 2014;23(1):172–178. doi: 10.1158/1055-9965.EPI-13-0447.
    1. Risch HA. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst. 2003;95(13):948–960. doi: 10.1093/jnci/95.13.948.
    1. Chen XZ, Schottker B, Castro FA, Chen H, Zhang Y, Holleczek B, Brenner H. Association of helicobacter pylori infection and chronic atrophic gastritis with risk of colonic, pancreatic and gastric cancer: A ten-year follow-up of the ESTHER cohort study. Oncotarget. 2016;7(13):17182–17193. doi: 10.18632/oncotarget.7946.
    1. Ben Q, Wang K, Yuan Y, Li Z. Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer. 2011;128(5):1179–1186. doi: 10.1002/ijc.25426.
    1. Anstee DJ. The relationship between blood groups and disease. Blood. 2010;115(23):4635–4643. doi: 10.1182/blood-2010-01-261859.
    1. Liumbruno GM, Franchini M. Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus. 2013;11(4):491–499.
    1. Franchini M, Favaloro EJ, Targher G, Lippi G. ABO blood group, hypercoagulability, and cardiovascular and cancer risk. Crit Rev Clin Lab Sci. 2012;49(4):137–149. doi: 10.3109/10408363.2012.708647.
    1. Franchini M, Liumbruno GM, Lippi G. The prognostic value of ABO blood group in cancer patients. Blood Transfus. 2016;14(5):434–440.
    1. Zhang BL, He N, Huang YB, Song FJ, Chen KX. ABO blood groups and risk of cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2014;15(11):4643–4650. doi: 10.7314/APJCP.2014.15.11.4643.
    1. Macafee AL. ABO blood groups and carcinoma of pancreas. Ulster Med J. 1964;33(2):129–131.
    1. Vioque J, Walker AM. [Pancreatic cancer and ABO blood types: a study of cases and controls] Med Clin (Barc) 1991;96(20):761–764.
    1. Annese V, Minervini M, Gabbrielli A, Gambassi G, Manna R. ABO blood groups and cancer of the pancreas. Int J Pancreatol. 1990;6(2):81–88.
    1. Wolpin BM, Chan AT, Hartge P, Chanock SJ, Kraft P, Hunter DJ, Giovannucci EL. et al. ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2009;101(6):424–431. doi: 10.1093/jnci/djp020.
    1. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, Fuchs CS, Petersen GM, Arslan AA, Bueno-de-Mesquita HB. et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet. 2009;41(9):986–990. doi: 10.1038/ng.429.
    1. Rizzato C, Campa D, Giese N, Werner J, Rachakonda PS, Kumar R, Schanne M. et al. Pancreatic cancer susceptibility loci and their role in survival. PLoS One. 2011;6(11):e27921. doi: 10.1371/journal.pone.0027921.
    1. Dandona M, Gao F, Linehan DC, Wang-Gillam A. Re: ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst. 2010;102(2):135–137. doi: 10.1093/jnci/djp447. author reply 137.
    1. Rahbari NN, Bork U, Hinz U, Leo A, Kirchberg J, Koch M, Buchler MW. et al. AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer. 2012;12:319.
    1. Wang DS, Wang ZQ, Zhang L, Qiu MZ, Luo HY, Ren C, Zhang DS. et al. Are risk factors associated with outcomes in pancreatic cancer? PLoS One. 2012;7(7):e41984. doi: 10.1371/journal.pone.0041984.
    1. Hakomori S. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta. 1999;1473(1):247–266. doi: 10.1016/S0304-4165(99)00183-X.
    1. Etemad B, Whitcomb DC. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology. 2001;120(3):682–707. doi: 10.1053/gast.2001.22586.
    1. Ekbom A, McLaughlin JK, Karlsson BM, Nyren O, Gridley G, Adami HO, Fraumeni JF Jr. Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst. 1994;86(8):625–627. doi: 10.1093/jnci/86.8.625.
    1. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol. 2010;24(3):349–358. doi: 10.1016/j.bpg.2010.02.007.
    1. Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, Silverman DT. et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4) Ann Oncol. 2012;23(11):2964–2970. doi: 10.1093/annonc/mds140.
    1. Yadav D, Whitcomb DC. The role of alcohol and smoking in pancreatitis. Nat Rev Gastroenterol Hepatol. 2010;7(3):131–145. doi: 10.1038/nrgastro.2010.6.
    1. Hirota M, Shimosegawa T, Masamune A, Kikuta K, Kume K, Hamada S, Kihara Y. et al. The sixth nationwide epidemiological survey of chronic pancreatitis in Japan. Pancreatology. 2012;12(2):79–84. doi: 10.1016/j.pan.2012.02.005.
    1. Lowenfels AB, Maisonneuve P, Cavallini G, Ammann RW, Lankisch PG, Andersen JR, Dimagno EP. et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993;328(20):1433–1437. doi: 10.1056/NEJM199305203282001.
    1. Bracci PM, Wang F, Hassan MM, Gupta S, Li D, Holly EA. Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control. 2009;20(9):1723–1731. doi: 10.1007/s10552-009-9424-x.
    1. Olson SH. Selected medical conditions and risk of pancreatic cancer. Mol Carcinog. 2012;51(1):75–97. doi: 10.1002/mc.20816.
    1. Midha S, Sreenivas V, Kabra M, Chattopadhyay TK, Joshi YK, Garg PK. Genetically determined chronic pancreatitis but not alcoholic pancreatitis is a strong risk factor for pancreatic cancer. Pancreas. 2016;45(10):1478–1484. doi: 10.1097/MPA.0000000000000684.
    1. Whitcomb DC. Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2004;287(2):G315–319. doi: 10.1152/ajpgi.00115.2004.
    1. Lowenfels AB, Maisonneuve P, Whitcomb DC. Risk factors for cancer in hereditary pancreatitis. International Hereditary Pancreatitis Study Group. Med Clin North Am. 2000;84(3):565–573. doi: 10.1016/S0025-7125(05)70240-6.
    1. Howes N, Lerch MM, Greenhalf W, Stocken DD, Ellis I, Simon P, Truninger K. et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol. 2004;2(3):252–261. doi: 10.1016/S1542-3565(04)00013-8.
    1. Raimondi S, Maisonneuve P, Lohr JM, Lowenfels AB. Early onset pancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev. 2007;16(9):1894–1897. doi: 10.1158/1055-9965.EPI-07-0341.
    1. Lowenfels AB, Maisonneuve P, DiMagno EP, Elitsur Y, Gates LK Jr, Perrault J, Whitcomb DC. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst. 1997;89(6):442–446. doi: 10.1093/jnci/89.6.442.
    1. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286(2):169–170. doi: 10.1001/jama.286.2.169.
    1. Greenhalf W, Grocock C, Harcus M, Neoptolemos J. Screening of high-risk families for pancreatic cancer. Pancreatology. 2009;9(3):215–222. doi: 10.1159/000210262.
    1. Shin EJ, Canto MI. Pancreatic cancer screening. Gastroenterol Clin North Am. 2012;41(1):143–157. doi: 10.1016/j.gtc.2011.12.001.
    1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–1617. doi: 10.1056/NEJMra0901557.
    1. Cappelli G, Paladini S, D'Agata A. [Tumor markers in the diagnosis of pancreatic cancer] Tumori. 1999;85(1 Suppl 1):S19–21. doi: 10.1177/030089169908501s06.
    1. Walsh RM, Vogt DP, Henderson JM, Hirose K, Mason T, Bencsath K, Hammel J. et al. Management of suspected pancreatic cystic neoplasms based on cyst size. Surgery. 2008;144(4):677–684. discussion 684-675.
    1. Tanaka M, Fernandez-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, Kimura W. et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–197. doi: 10.1016/j.pan.2012.04.004.
    1. Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, Ali SZ. et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2(7):606–621. doi: 10.1016/S1542-3565(04)00244-7.
    1. Vitone LJ, Greenhalf W, Howes NR, Neoptolemos JP. Hereditary pancreatitis and secondary screening for early pancreatic cancer. Rocz Akad Med Bialymst. 2005;50:73–84.
    1. American gastroenterological association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 1999;117(6):1463–1484. doi: 10.1016/S0016-5085(99)70297-0.
    1. Krech RL, Walsh D. Symptoms of pancreatic cancer. J Pain Symptom Manage. 1991;6(6):360–367. doi: 10.1016/0885-3924(91)90027-2.
    1. Klauss M, Schobinger M, Wolf I, Werner J, Meinzer HP, Kauczor HU, Grenacher L. Value of three-dimensional reconstructions in pancreatic carcinoma using multidetector CT: initial results. World J Gastroenterol. 2009;15(46):5827–5832. doi: 10.3748/wjg.15.5827.
    1. Wong JC, Lu DS. Staging of pancreatic adenocarcinoma by imaging studies. Clin Gastroenterol Hepatol. 2008;6(12):1301–1308. doi: 10.1016/j.cgh.2008.09.014.
    1. Harewood GC, Wiersema MJ. Endosonography-guided fine needle aspiration biopsy in the evaluation of pancreatic masses. Am J Gastroenterol. 2002;97(6):1386–1391. doi: 10.1111/j.1572-0241.2002.05777.x.
    1. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd. et al. Pancreatic adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(8):1028–1061. doi: 10.6004/jnccn.2017.0131.
    1. Safi F, Roscher R, Bittner R, Schenkluhn B, Dopfer HP, Beger HG. High sensitivity and specificity of CA 19-9 for pancreatic carcinoma in comparison to chronic pancreatitis. Serological and immunohistochemical findings. Pancreas. 1987;2(4):398–403. doi: 10.1097/00006676-198707000-00006.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi